{"title":"[The current role of isavuconazole in the treatment of invasive fungal infections].","authors":"Ondrej Zahornacky, Pavol Jarčuška","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Significant medical advances in the treatment and management of immunocompromised patients are currently leading to an ever-increasing incidence of invasive fungal infections (IFI). Due to the limited antifungal treatment options, the management of IFI remains a major challenge. The triazole antifungal drug isavuconazole (ISV) shows a broader spectrum of activity against Mucorales isolates and represents another therapeutic option for difficult-to-treat IFI. ISV is a broad-spectrum triazole antifungal II. generation, which is primarily intended for the treatment of invasive aspergillosis and mucormycosis, but in the future it also represents a promising therapeutic option for the treatment of other, rare IFIs (cryptococcosis, infections caused by dimorphic fungi). The article summarizes the basic knowledge and provides a brief overview of the pharmacodynamics, pharmacokinetics, mechanism of action, metabolism, indications, and dosage of isavuconazole in clinical practice. It also includes a brief analysis of selected clinical trials (SECURE, ACTIVE, VITAL) and recommendations of individual international societies.</p>","PeriodicalId":17909,"journal":{"name":"Klinicka mikrobiologie a infekcni lekarstvi","volume":"29 4","pages":"116-119"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicka mikrobiologie a infekcni lekarstvi","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Significant medical advances in the treatment and management of immunocompromised patients are currently leading to an ever-increasing incidence of invasive fungal infections (IFI). Due to the limited antifungal treatment options, the management of IFI remains a major challenge. The triazole antifungal drug isavuconazole (ISV) shows a broader spectrum of activity against Mucorales isolates and represents another therapeutic option for difficult-to-treat IFI. ISV is a broad-spectrum triazole antifungal II. generation, which is primarily intended for the treatment of invasive aspergillosis and mucormycosis, but in the future it also represents a promising therapeutic option for the treatment of other, rare IFIs (cryptococcosis, infections caused by dimorphic fungi). The article summarizes the basic knowledge and provides a brief overview of the pharmacodynamics, pharmacokinetics, mechanism of action, metabolism, indications, and dosage of isavuconazole in clinical practice. It also includes a brief analysis of selected clinical trials (SECURE, ACTIVE, VITAL) and recommendations of individual international societies.